UPDATE: GlaxoSmithKline (GSK) Sees Double-Digit FY16 Core EPS Growh - JPMorgan Conf.

(Updated - January 12, 2016 12:02 PM EST)

GlaxoSmithKline (NYSE: GSK) sees FY16 core EPS with double-digit growth, according to Bloomberg. The company expects FY16 - 20 core EPS up mid-to-high single-digit CAGR.

Glaxo sees FY15 - FY17 annual ordinary dividend at 80 pence per share. The company is also planning a 20 pence special dividend with the Q4 dividend.

Glaxo is presenting at the 34th Annual JPMorgan Healthcare conference today. The company's presentation is embedded below:

You May Also Be Interested In

• Biogen (BIIB) tops earnings expectations but revenue falls short
• Illinois Tool Works (ITW) PT Lowered to $280 at JPMorgan
• General Motors (GM) PT Raised to $60 at JPMorgan